Maravai LifeSciences Appoints Trey Martin to Board of Directors
Maravai LifeSciences (NASDAQ: MRVI) has announced the appointment of CEO William "Trey" Martin, III to its Board of Directors, effective July 31, 2024. This strategic move highlights Martin's leadership, commitment to innovation, and extensive industry experience. Carl Hull, Maravai's co-founder and Executive Chair, expressed confidence in Martin's ability to enhance decision-making and help deliver on the company's return to growth strategy.
Martin, who has served as Maravai's CEO since July 2023, brings over 25 years of executive leadership experience in life sciences. His appointment is expected to strengthen the connection between the Board and day-to-day operations, ensuring responsiveness to key issues. Martin expressed his commitment to building a strong foundation for long-term, sustainable growth of Maravai's businesses.
Maravai LifeSciences (NASDAQ: MRVI) ha annunciato la nomina di William "Trey" Martin, III come membro del Consiglio di Amministrazione, con effetto dal 31 luglio 2024. Questa mossa strategica sottolinea la leadership di Martin, il suo impegno per l'innovazione e la sua vasta esperienza nel settore. Carl Hull, co-fondatore di Maravai e Presidente Esecutivo, ha espresso fiducia nella capacità di Martin di migliorare il processo decisionale e contribuire alla realizzazione della strategia di ritorno alla crescita dell'azienda.
Martin, che ricopre il ruolo di CEO di Maravai dal luglio 2023, porta con sé oltre 25 anni di esperienza nella leadership esecutiva nel settore delle scienze della vita. La sua nomina è prevista per rafforzare il collegamento tra il Consiglio e le operazioni quotidiane, garantendo una pronta risposta a questioni fondamentali. Martin ha espresso il suo impegno a costruire una solida base per una crescita sostenibile e a lungo termine delle attività di Maravai.
Maravai LifeSciences (NASDAQ: MRVI) ha anunciado el nombramiento de William "Trey" Martin, III a su Junta Directiva, con efecto a partir del 31 de julio de 2024. Este movimiento estratégico resalta el liderazgo de Martin, su compromiso con la innovación y su amplia experiencia en la industria. Carl Hull, cofundador de Maravai y Presidente Ejecutivo, expresó confianza en la capacidad de Martin para mejorar la toma de decisiones y ayudar a ejecutar la estrategia de retorno al crecimiento de la empresa.
Martin, que ha sido CEO de Maravai desde julio de 2023, aporta más de 25 años de experiencia en liderazgo ejecutivo en ciencias de la vida. Se espera que su nombramiento fortalezca la conexión entre la Junta y las operaciones diarias, asegurando una respuesta adecuada a temas clave. Martin manifestó su compromiso de construir una sólida base para el crecimiento sostenible a largo plazo de los negocios de Maravai.
Maravai LifeSciences (NASDAQ: MRVI)는 William "Trey" Martin, III를 이사로 임명한다고 발표했습니다. 이 결정은 2024년 7월 31일부터 시행됩니다. 이 전략적인 조치는 Martin의 리더십, 혁신에 대한 헌신, 그리고 방대한 산업 경험을 강조합니다. Maravai의 공동 창립자이자 집행 의장인 Carl Hull은 Martin이 의사 결정 개선에 기여하고 회사의 성장 복귀 전략을 실행하는 데 도움을 줄 것이라는 믿음을 표명했습니다.
Martin은 2023년 7월부터 Maravai의 CEO로 재직 중이며, 생명 과학 분야에서 25년 이상의 경영진 리더십 경험을 보유하고 있습니다. 그의 임명은 이사회와 일상 운영 간의 연결을 강화하여 핵심 사안에 대한 즉각적인 대응을 보장할 것으로 기대됩니다. Martin은 Maravai 비즈니스의 장기적이고 지속 가능한 성장을 위한 강력한 기반을 구축하겠다는 의지를 표명했습니다.
Maravai LifeSciences (NASDAQ: MRVI) a annoncé la nomination de William "Trey" Martin, III à son Conseil d'administration, avec effet à partir du 31 juillet 2024. Ce mouvement stratégique met en lumière le leadership de Martin, son engagement envers l'innovation et sa vaste expérience dans l'industrie. Carl Hull, co-fondateur de Maravai et Président exécutif, a exprimé sa confiance dans la capacité de Martin à améliorer la prise de décision et à contribuer à la mise en œuvre de la stratégie de retour à la croissance de l'entreprise.
Martin, qui est PDG de Maravai depuis juillet 2023, apporte plus de 25 ans d'expérience en leadership exécutif dans le domaine des sciences de la vie. Sa nomination devrait renforcer le lien entre le Conseil et les opérations quotidiennes, garantissant une réactivité face aux enjeux clés. Martin a exprimé son engagement à établir une base solide pour la croissance durable à long terme des activités de Maravai.
Maravai LifeSciences (NASDAQ: MRVI) hat die Ernennung von William "Trey" Martin, III zum Mitglied des Vorstands bekannt gegeben, die am 31. Juli 2024 wirksam wird. Dieser strategische Schritt hebt Martins Führung, sein Engagement für Innovation und seine umfassende Branchenerfahrung hervor. Carl Hull, Mitbegründer von Maravai und Executive Chairman, äußerte Vertrauen in Martins Fähigkeit, die Entscheidungsfindung zu verbessern und zur Umsetzung der Wachstumsstrategie des Unternehmens beizutragen.
Martin, der seit Juli 2023 CEO von Maravai ist, bringt über 25 Jahre Erfahrung in der Führungsebene der Lebenswissenschaften mit. Seine Ernennung wird voraussichtlich die Verbindung zwischen dem Vorstand und dem operativen Geschäft stärken, um eine schnelle Reaktion auf wichtige Themen sicherzustellen. Martin bekundete sein Engagement, eine solide Basis für nachhaltiges und langfristiges Wachstum der Geschäftstätigkeiten von Maravai zu schaffen.
- CEO Trey Martin appointed to Board of Directors, potentially improving strategic alignment
- Martin brings 25+ years of executive leadership experience in life sciences
- Appointment expected to enhance decision-making and responsiveness to key issues
- None.
Maravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that its CEO William “Trey” Martin, III has been appointed to the Company’s Board of Directors, effective July 31, 2024. This strategic appointment underscores Martin’s commitment to innovation, leadership capabilities, and deep industry knowledge.
“We are thrilled to welcome Trey to our Board of Directors,” said Carl Hull, Maravai’s co-founder and Executive Chair of its Board of Directors. “Trey’s extensive experience and depth of knowledge will bring valuable perspectives and enrich our collective decision-making. His close connection to our markets, customers, and employees will undoubtedly enhance our ability to navigate emergent risks and seize opportunities. Trey’s presence reinforces the bridge between our Board and our day-to-day operations, ensuring we remain deeply connected and responsive to the issues that matter most. Since his assumption of the CEO role last year, the Board has been impressed with his leadership capabilities and we believe his contributions to our Board will help Maravai deliver on our return to growth strategy and achieve our ambitious objectives.”
“I am honored to join Maravai’s Board of Directors and will continue to work closely with our exceptional team,” Martin said. “I remain confident in the fundamental strength of our end markets, and the value we provide our customers for the life-changing development of drug therapies, diagnostics and novel vaccines. Together with the Board, I am committed to building a strong foundation for long-term, sustainable growth of our businesses.”
Mr. Martin has more than 25 years of executive leadership experience in life sciences operations, engineering, sales, product development and marketing. Since July 2023, he has served as Maravai’s Chief Executive Officer. From December 2022 to July 2023, Mr. Martin served as President, Biologics Safety Testing at Maravai. Prior to that, he was Senior Vice President, Genomic Medicines, at Danaher Corporation. Mr. Martin originally joined Danaher with the acquisition of Integrated DNA Technologies (IDT) in 2018 and served as President of the IDT business there for over three years. Prior to its acquisition, Mr. Martin held positions of increasing responsibility over more than two decades at IDT, and contributed to the consistent growth and competitiveness of the company’s genomic solutions business through organic and inorganic growth investments. Mr. Martin holds a Bachelor’s in biochemistry from the University of Iowa.
Martin joins Maravai Executive Chair Carl Hull, as one of two executives on the Company’s Board.
Martin has been appointed to fill the vacancy on the Board that will be created by Anat Ashkenazi’s previously-disclosed resignation.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Forward-looking Statements
This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to the expectation that Mr. Martin will drive Maravai’s growth strategy and objectives, constitute forward-looking statements identified by words like “plan,” “will,” “expect,” “believe,” “may,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including, without limitation, continued demand for our COVID-19 related products and services, which currently comprise a significant portion of our revenue, and the other risks and uncertainties described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.
FAQ
When will Trey Martin join Maravai LifeSciences' Board of Directors?
What is Trey Martin's current role at Maravai LifeSciences (MRVI)?
How long has Trey Martin been with Maravai LifeSciences (MRVI)?
What is Maravai LifeSciences' (MRVI) primary business focus?
